


Supplemental Figure VIII, Rohde et al.



**Supplemental Figure VIII. Analysis of S100A1-mediated gene expression modifications and S100A1 influence on proliferation of cardiac fibroblasts.** **A**, S100A1-related upregulation of ICAM1 is blunted in TLR4 and MyD88 knock out fibroblasts (TLR4<sup>-/-</sup>, MyD88<sup>-/-</sup>) but not in RAGE knock out fibroblasts (RAGE<sup>-/-</sup>) (left panel: representative Western blots, right panel: RT-PCR results, n=3). **B**, S100A1-mediated ICAM1 and thrombospondin 2 (TSP-2) upregulation is abrogated by pre-incubation with NFκB inhibitor MG-132 (MG). Pre-treatment of cardiac fibroblasts with the ERK1/2 inhibitor PD98059 (PD) results in suspension of MMP9 upregulation in response to S100A1 (n=5; \*/#P-values vs co/S100A1: 0.002/0.01 for ICAM1, 0.02/0.01 for TSP-2, 0.01/0.003 for MMP9). **C-D**, Incubation of cardiac fibroblasts with S100A1 had no effect on proliferation measured as increase in cell number (**C**) or amount of incorporated <sup>3</sup>H-thymidine (**D**). Stimulation with FCS served as positive control for increased fibroblast proliferation (n=3; **C**: \*P-value vs co 0.001 for 48 and 72hrs; **D**: \*P=0.03 vs co).